XM does not provide services to residents of the United States of America.
I
I

Ipsen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Ipsen Ups FY Guidance, Posts Q3 Revenue Of EUR 836.6 Mln

BRIEF-Ipsen Ups FY Guidance, Posts Q3 Revenue Of EUR 836.6 Mln Oct 23 (Reuters) - Ipsen SA IPN.PA : IPSEN DELIVERS STRONG SALES MOMENTUM IN THE FIRST NINE MONTHS OF 2024 AND INCREASES ITS FULL-YEAR GUIDANCE Q3 REVENUE EUR 836.6 MILLION INCREASED 2024 FINANCIAL GUIDANCE 2024 GUIDANCE: TOTAL-SALES GROWTH GREATER THAN 8.0%, AT CONSTANT CURRENCY (PRIOR
I

US FDA declines to approve Camurus' rare hormone disorder drug

US FDA declines to approve Camurus' rare hormone disorder drug Oct 22 (Reuters) - The U.S. Food and Drug Administration has declined to approve Camurus' CAMX.ST drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday. WHY IT'S IMPORTANT The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of ev
I
N

UK's MHRA Says Elafibranor Approved To Treat Adults With A Rare Liver Disease Known As Primary Biliary Cholangitis (Oct. 8)

CORRECTED-(OFFICIAL)-BRIEF-UK's MHRA Says Elafibranor Approved To Treat Adults With A Rare Liver Disease Known As Primary Biliary Cholangitis (Oct. 8) Corrects Oct. 8 brief to remove reference to Elafibranor being approved as "first medicine" in headline and bullet after MHRA clarification Oct 15 (Reuters) - UK's MHRA: UK'S MHRA: ELAFIBRANOR APPROV
I

Ipsen’s Iqirvo Receives European Approval

BRIEF-Ipsen’s Iqirvo Receives European Approval Sept 20 (Reuters) - Ipsen SA IPN.PA : IPSEN’S IQIRVO® (ELAFIBRANOR) APPROVED IN THE EUROPEAN UNION AS FIRST NEW TREATMENT FOR PRIMARY BILIARY CHOLANGITIS IN NEARLY A DECADE APPROVAL FOLLOWS POSITIVE CHMP OPINION BASED ON ELATIVE PHASE III TRIAL DATA Source text for Workspace: ID:nGNX9KlXHf Furthe
I

Cenbank divergences ending, apart from Japan - Amundi

LIVE MARKETS-Cenbank divergences ending, apart from Japan - Amundi STOXX 600 up 1.3% Fed cuts by 50 bps, eyes on BoE Ocado top index after results Miners, autos surge, utilities down Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com CENBANK DIVERGENCES ENDING, APART FROM JAPAN - AMUNDI It has been an eventful week for central bank activity.
F
I
S
E
F
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.